Society of American Gastrointestinal and Endoscopic Surgeons

TELA Bio’s OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023

Retrieved on: 
Wednesday, March 29, 2023

These case reports will help inform surgeons on techniques related to the use of OviTex in robot-assisted hernia repair.

Key Points: 
  • These case reports will help inform surgeons on techniques related to the use of OviTex in robot-assisted hernia repair.
  • OviTex Reinforced Tissue Matrix is uniquely positioned as a tissue-derived hernia reinforcement option that can be utilized successfully in robotic and laparoscopic hernia repairs.
  • “We’re excited and appreciative to see the use of OviTex in robotic hernia repair highlighted at SAGES,” said Antony Koblish, CEO of TELA Bio.
  • Florida State University, University of Florida)
    The TELA Bio team will be attending SAGES 2023, Booth #301.

Theator Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023

Retrieved on: 
Thursday, March 2, 2023

Palo Alto, California, March 02, 2023 (GLOBE NEWSWIRE) -- Theator, a software platform that leverages AI and computer vision technology to help hospitals improve the quality of surgical care, has been named to Fast Company’s annual list of the World’s Most Innovative Companies for 2023.

Key Points: 
  • Palo Alto, California, March 02, 2023 (GLOBE NEWSWIRE) -- Theator, a software platform that leverages AI and computer vision technology to help hospitals improve the quality of surgical care, has been named to Fast Company’s annual list of the World’s Most Innovative Companies for 2023.
  • This is the second time the Surgical Intelligence company has made Fast Company’s prestigious annual list of Most Innovative Companies.
  • The World’s Most Innovative Companies is Fast Company’s signature franchise and one of its most highly anticipated editorial efforts of the year.
  • Everyone on this list does something completely, uniquely different, yet, they all have one thing in common: innovation,” said Fast Company editor-in-chief Brendan Vaughan.

The Academy for Surgical Coaching and SAGES Pilot First-of-its-Kind Coaching Program for Gastrointestinal and Endoscopic Surgeons as They Transition to Practice

Retrieved on: 
Wednesday, December 14, 2022

LOS ANGELES, Dec. 14, 2022 /PRNewswire/ -- The Academy for Surgical Coaching, a surgical education organization that empowers surgeons to improve their performance through coaching, and supported by analytics capabilities from Intuitive Surgical, today announced that the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), the largest professional society for GI surgeons, will partner with The Academy to pilot the SAGES Surgical Coaching Program.

Key Points: 
  • LOS ANGELES, Dec. 14, 2022 /PRNewswire/ -- The Academy for Surgical Coaching, a surgical education organization that empowers surgeons to improve their performance through coaching, and supported by analytics capabilities from Intuitive Surgical, today announced that the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), the largest professional society for GI surgeons, will partner with The Academy to pilot the SAGES Surgical Coaching Program.
  • The SAGES Surgical Coaching Program will support SAGES members as they transition from training to practice through collaboration with Academy-trained Surgical Coaches to help new-to-practice surgeons transition into the role of practicing surgeon.
  • The Academy for Surgical Coaching trains surgeons to become Surgical Coaches, pairs surgeons with Surgical Coaches, and manages coaching programs.
  • The Academy for Surgical Coaching has trained over 250 Surgical Coaches and conducted over 400 hours of surgical coaching.

SAGES Extends Partnership with Theator on Additional Video-Based Assessments

Retrieved on: 
Wednesday, September 14, 2022

The previously announced pilot agreement for laparoscopic Nissen fundoplication has been extended to include additional surgical procedure types.

Key Points: 
  • The previously announced pilot agreement for laparoscopic Nissen fundoplication has been extended to include additional surgical procedure types.
  • The renewed agreement is part of SAGES' video-based assessment (VBA) program to measure competency for the relevant procedures.
  • Theator is partnering with leading surgeons, hospitals, professional societies, and research institutions to create a smarter, more transparent operating room.
  • SAGES mission is to innovate, educate and collaborate to improve patient care with a vision of reimagining surgical care for a healthier world.

Theator Extends Series A Funding with Additional $24M for a Total of $39.5M

Retrieved on: 
Friday, July 22, 2022

PALO ALTO, Calif., July 22, 2022 /PRNewswire/ -- Theator, the creator of Surgical Intelligence, announced today that it has raised $24M in an extension of its Series A funding round. This extension follows an initial $15.5M Series A round announced in February 2021, bringing the round total to $39.5M. The extended funding round was once again led by Insight Partners with support from existing investors including Blumberg Capital, Mayo Clinic, NFX, StageOne Ventures, iAngels, and former Netflix Chief Product Officer Neil Hunt. In addition, new growth investors including iCON and TripActions' CEO and Co-founder Ariel Cohen joined the round.

Key Points: 
  • PALO ALTO, Calif., July 22, 2022 /PRNewswire/ -- Theator , the creator of Surgical Intelligence, announced today that it has raised $24M in an extension of its Series A funding round.
  • This extension follows an initial $15.5M Series A round announced in February 2021, bringing the round total to $39.5M.
  • The series extension comes on the heels of significant commercial traction, including Theator's expansion into Urology earlier this year.
  • Theator is pioneering Surgical Intelligence to eliminate the paradigm that where you live determines if you live.

CDx Diagnostics’ ​​WATS3D Participates in Highmark, Inc. Health Plans in Delaware, Pennsylvania, and West Virginia

Retrieved on: 
Thursday, May 19, 2022

WATS3D, an AI-powered diagnostic platform developed by CDx Diagnostics to empower physicians to reliably detect Barretts esophagus (BE) and esophageal dysplasia to help prevent esophageal cancer, was designated as medically necessary by Highmark, Inc. health plans in Delaware, Pennsylvania, and West Virginia in Q4 2021.

Key Points: 
  • WATS3D, an AI-powered diagnostic platform developed by CDx Diagnostics to empower physicians to reliably detect Barretts esophagus (BE) and esophageal dysplasia to help prevent esophageal cancer, was designated as medically necessary by Highmark, Inc. health plans in Delaware, Pennsylvania, and West Virginia in Q4 2021.
  • CDx Diagnostics is pleased to share, that effective immediately, WATS3D is now considered an in-network procedure as CDx Diagnostics participates in the Commercial and Medicare networks of these Highmark, Inc. plans.
  • Empowering physicians to preempt esophageal cancer and improve patient lives is what drives us.
  • Since 2019, the ASGE has included WATS3D in its Standards of Practice Committees guideline for the screening and surveillance of BE.

Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, May 13, 2022

CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported its financial results for the quarter ended March 31, 2022.

Key Points: 
  • CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported its financial results for the quarter ended March 31, 2022.
  • Additionally, we made progress on the financial front by bolstering our cash position with the completed financing, commented Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio.
  • The leadership team and board are focused on building on our momentum with our pipeline and look forward to unlocking value for all stakeholders of Palisade Bio.
  • The therapy is being developed for administration prior to surgeries that are at risk of disrupting the intestinal epithelial barrier.

Palisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements

Retrieved on: 
Monday, May 2, 2022

CARLSBAD,Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provided a business outlook and outlined its expected near-term pipeline advancements.

Key Points: 
  • CARLSBAD,Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provided a business outlook and outlined its expected near-term pipeline advancements.
  • Additionally, LB1148 has the potential to reduce abdominal adhesions a problem that can cause an alarming number of post-surgery complications.
  • The therapy is being developed for administration prior to major surgeries that are at risk of disrupting the intestinal epithelial barrier.
  • Evidence suggests that the release of digestive proteases contributes to the temporary loss of normal gastrointestinal function and the formation of postoperative adhesions.

Multidisciplinary Approach to Weight Management - Including Bariatric Surgery - Is a Viable Option for Adolescents with Obesity

Retrieved on: 
Monday, April 11, 2022

NEW YORK, April 11, 2022 /PRNewswire/ -- Increased access to an adolescent-centered healthy weight management program, including bariatric or weight loss surgery, is paramount to achieving the best long-term outcomes as adolescents with obesity grow to adulthood, a new study confirms.

Key Points: 
  • NEW YORK, April 11, 2022 /PRNewswire/ -- Increased access to an adolescent-centered healthy weight management program, including bariatric or weight loss surgery, is paramount to achieving the best long-term outcomes as adolescents with obesity grow to adulthood, a new study confirms.
  • Childhood obesity occurs when a child is well above the healthy weight for their age and height.
  • "Adolescents and teens with severe obesity face many significant barriers to accessing metabolic bariatric surgery, and while they wait, obesity-related comorbidities may continue to develop and impact their health.
  • Further research about how long-term comorbidities develop in adolescents with obesity is warranted for further understanding of the benefits of early bariatric surgery intervention.

ColoWrap Shortens Procedure Time During Colonoscopy, Increases Physician and Staff Satisfaction -- Data Presented at "The Next Big Thing" Session at SAGES 2022

Retrieved on: 
Tuesday, April 5, 2022

DURHAM, N.C., April 5, 2022 /PRNewswire-PRWeb/ -- ColoWrap, LLC., the early-stage medical technology company behind the first and only anti-looping colonoscopy compression device, today announced two abstracts highlighting the technology's ability to reduce procedure time and address ergonomic risks during colonoscopy that were selected for presentation during the Society for American Gastrointestinal and Endoscopic Surgeons (SAGES) 2022 Annual Meeting. SAGES 2022 was held from March 16 through March 19 in Denver, Colorado.

Key Points: 
  • Presented as part of the SAGES' "Next Big Thing" session was "ColoWrap Colonoscopy Compression Device Shortens Procedure Time and Increases Physician and Staff Satisfaction."
  • At Northfield, ColoWrap use reduced average cecal intubation time by 3.6 minutes and reduced procedure time by 5 minutes per case.
  • ColoWrap Colonoscopy Compression Device Shortens Procedure Time and Increases Physician and Staff Satisfaction, SAGES Conference, Denver, CO. https://eventpilot.us/web/page.php?page=IntHtml&project=SAGES22&id=121734
    2.
  • Preventing Staff Injury and Enhancing Satisfaction: Results from Use of ColoWrap Colonoscopy Compression Device in High-Volume Endoscopy Unit, SAGES Conference, Denver, CO. https://epostersonline.com/sages2022/poster/etp421?view=true